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INTRODUCTION
Malignancies are typically diagnosed later in life,
but it does not mean that the disease cannot be
sustained in young age. There are several types of
malignancies that can affect children and young
adults.
Cancer therapy has evolved significantly in re-
cent decades. With a better understanding of the
pathophysiology of the disease, screening tests are
becoming increasingly effective in diagnosing ma-
lignancy in human so that it can be diagnosed at
an earlier stage. Early diagnosis aided by conser-
vative treatment can increase the life expectancy
of cancer patients.1
At present, therapy for advanced-stage malig-
nancies has also become better. Radiotherapy can
localize specific organ or tumor so healthy tissue
damage can be minimized. Currently available che-
motherapy has minimal side effects, and surgery
nowadays has become more conservative. The de-
Abstract
Along with the development of cancer diagnosis and treatment, the
life expectancy of women in reproductive age who suffer from can-
cer are also higher. Women with cancer still have the possibility to
be pregnant and have a child during or after completion of therapy.
Taking this into consideration, the guideline for contraception in
special circumstances like this is needed. After reviewing the safety
and effectiveness of contraceptive methods available for women
with cancer, The Society of Family Planning urged not to use combi-
nation hormonal contraceptives (estrogen and progestin). Hormo-
nal contraceptive use in cancer patients may increase the risk of ve-
nous thromboembolism (Level A). T380A IUD, which has a high ef-
fectiveness, reversible, long-term, and hormone-free contraception
should be considered as the primary choice in patients with breast
cancer (Level A). In women who received tamoxifen therapy, the use
of IUD containing Levonorgestrel can be considered as a second
choice (Level B) because it can decrease the proliferation en-
dometrium. Women with anemia due to chemotherapy may be
given contraceptive containing progestin (Level A). Women with
osteopenia or osteoporosis after chemotherapy should avoid pro-
gestin contraceptive injection (Level A). Currently, there are no data
to evaluate the risk of venous thromboembolism in progestin con-
traceptive use. Further information is also needed to determine the
effect of the use of IUD that contains Levonorgestrel against breast
cancer recurrence and the effect of hormonal contraceptives on
breast cancer in women who received chest wall radiotherapy.
[Indones J Obstet Gynecol 2014; 3: 166-170]
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Abstrak
Seiring dengan perkembangan diagnosis dan terapi kanker yang se-
makin baik, angka harapan hidup wanita usia reproduksi yang men-
derita kanker juga semakin tinggi. Wanita penderita kanker masih
mungkin hamil dan memiliki anak selama atau setelah menyelesaikan
terapi. Dengan begitu, diperlukan pedoman kontrasepsi dalam kea-
daan khusus seperti ini. Setelah melakukan tinjauan keamanan dan
efektivitas metode kontrasepsi yang tersedia untuk wanita penderita
kanker, Society of Family Planning menghimbau untuk tidak menggu-
nakan kontrasepsi hormonal kombinasi (estrogen dan progestin).
Penggunaan kontrasepsi hormonal pada penderita kanker dapat
meningkatkan risiko terjadinya tromboemboli vena (Level A). AKDR
T380A yang memiliki efektivitas tinggi, reversibel, jangka panjang,
dan bebas hormon harus dipertimbangkan sebagai kontrasepsi pili-
han utama pada penderita kanker payudara (Level A). Pada wanita
yang mendapat terapi Tamoxifen, penggunaan AKDR yang mengan-
dung Levonorgestrel dapat dipertimbangkan sebagai pilihan kedua
(Level B) karena dapat menurunkan proliferasi endometrium. Wanita
dengan anemia karena kemoterapi dapat diberikan kontrasepsi yang
mengandung progestin (Level A). Wanita dengan osteopenia atau
osteoporosis setelah kemoterapi harus menghindari injeksi kontra-
sepsi progestin (Level A). Saat ini, belum ada data untuk evaluasi risiko
tromboemboli vena pada penggunaan kontrasepsi progestin. Diper-
lukan juga Informasi lebih jauh untuk mengetahui pengaruh penggu-
naan AKDR yang mengandung Levonorgestrel terhadap rekurensi
kanker payudara dan pengaruh kontrasepsi hormonal pada pende-
rita kanker payudara pada wanita yang mendapatkan radioterapi di
dinding dada.
[Maj Obstet Ginekol Indones 2014; 3: 166-170]
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velopment of diagnosis and treatment resulted in
an increase of life expectancy for cancer patients.
A woman of reproductive age suffering from cancer
and undergoing treatment can remain fertile dur-
ing therapy and thereafter. For that, pregnancy and
birth control are still necessary issues, as well as
family planning.
Another problem in family planning that needs
to be considered in patients with cancer is the tera-
togenic effects of chemotherapy and radiotherapy.
Therefore, contraception must be used during
treatment and for up to six months after comple-
tion of chemotherapy or radiotherapy. Contracep-
tive methods available today vary widely and each
has different side effects. The effectiveness and side
effects of each contraceptive may guide clinicians




There are six classes of contraceptive methods: be-
havioral methods, barrier methods, estrogen-con-
taining methods, progestin-only methods, intrau-
terine devices (IUD), and surgical sterilization.
There are pros and cons to each of these methods.
Although contraceptive efficacy is frequently dis-
cussed in the context of 1-year failure rates, it is a
very important consideration for women who re-
quire long-term contraception. In the long term,
IUDs, contraceptive implants, and sterilization are
significantly more effective than barrier methods
or birth control pills. Unfortunately, birth control
pills are still the most frequently chosen meth-
ods.3,4
Family Planning Association has issued guide-
lines for contraceptive options for women with
cancer. Although in some cases, chemotherapy and
radiotherapy can reduce fertility, many women are
still fertile. Anti-Mullerian hormone test is a diag-
nostic tool to determine the appropriate number
of follicles that are still available.
Hormones play an important role in the deve-
lopment of breast cancer. Therefore, the use of
combined oral contraceptives or progestin pills are
not recommended in patients with breast cancer.
In women with breast cancer, intrauterine device
(IUD) is the best contraceptive choice. For women
receiving tamoxifen therapy as part of treatment
regimens, contraceptive intrauterine systems (IUS)
provide the most benefits. This contraceptive
works against proliferative effects of tamoxifen on
the endometrium.
Cancer increases the risk of venous thromboem-
bolism. Therefore, the combination contraceptive
of estrogen/progestin is not recommended in pa-
tients with cancer. However, this type of contra-
ception can still be used in cancer patients with
anemia because it can reduce blood loss during
menstruation.5,6
Assessment of Fertility in Patients with
Cancer
Pregnancy has been reported in patients who sur-
vive from cancer although they are suffering from
amenorrhea with menopausal FSH levels.7,8 This
suggests that the absence of menstruation is not
an indication of diminished ovarian function.9
Therefore, a variety of biochemical tests (including
the level of FSH, inhibin A or B level, or the Anti-
Mullerian hormone) and biophysical tests (trans-
vaginal ultrasound) should be used to estimate the
ovarian reserve. Today, anti-Mullerian hormone
levels are considered to be the best predictor of a
woman’s fertility. Ways to identify whether a wo-
man is still fertile after chemotherapy is still under
investigation at this time.10-12
Primary Cancer Affecting the Selection of
Contraception
Several types of cancers can affect the selection of
contraception, especially in patients with breast
cancer or other cancers that are hormone medi-
ated. In women with breast cancer, exogenous es-
trogen and progesterone are not recommended be-
cause it increases the risk of recurrence. Estrogen
and progestin receptor status influence tumor
growth and thus estrogen receptor blockade is a
main component of breast cancer treatment. Ta-
moxifen therapies can cause endometrial prolifera-
tion and endometrial cancer. Therefore, contracep-
tive intrauterine system containing Levonorgestrel
is the most favorable choice because it can reduce
endometrial proliferation.13
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Selection of Contraception in Gynecologic
Malignancies
Gestational Trophoblastic Disease
In patients with gestational trophoblastic disease,
patients are encouraged to delay pregnancy until
therapy is completed. Patients receiving chemo-
therapy is recommended to postpone pregnancy
until one year after completion of therapy. There-
fore, contraception is required to delay pregnancy.
Women with gestational trophoblastic disease is
recommended to use barrier method of contracep-
tion since the time of diagnosis until  -hCG levels
became normal. When  -hCG reaches normal lev-
els, contraception can be continued using combi-
nation contraceptive pills. There is strong evidence
that progesterone pill has a better effect than com-
bination pill.14
Germinal Ovarian Cancer Cells
The prevalence of ovarian germ cell tumors is 20-
25% of all ovarian neoplasia with only about 3%
turning out to be malignant. Since the mid 1980’s,
fertility-preserving surgery, which entails remov-
ing the affected ovary and preserving the contralat-
eral ovary and the uterus, followed by combination
chemotherapy has become the standard procedure
for early stages and selected advanced malignant
germ cell tumors of the ovary. The main advantage
of this therapy is that patients with malignant germ
cell tumors of the ovary could conserve their re-
productive function after effective treatment. Low
et al. reported 74 patients with germ cell ovarian
cancer who received conservative surgery, 47 pa-
tients of whom received adjuvant chemotherapy,
20 patients attempted conception, and 19 patients
were successful.15,16 However, conception should
be avoided during chemotherapy because of the
teratogenic side effects of chemotherapy. The rec-
ommended contraception is combination pill or
progesterone only pill.17
The Risk of Venous Thromboembolism Af-
fecting the Selection of Contraception
Both cancer and estrogen are independent risk fac-
tors for the occurrence of venous thromboembo-
lism. Cancer patients with venous thromboembo-
lism have doubled risk of mortality compared to
those without venous thromboembolism. It is ob-
vious that thromboembolism is one of the causes
of death in cancer patients. Lung, lymphatic system,
gynecologic, and genitourinary cancers have a high
risk for venous thromboembolism.18
Due to the increased risk of venous thromboem-
bolism, the World Health Organization (WHO) and
the Centers for Disease Control and Prevention
(CDC) recommend that women with active cancer
or who have been treated for cancer in the last 6
months avoid combined hormonal contraceptive
methods (Category 4). Progestin-only contracep-
tives increase the risk of venous thromboembolism
much less than estrogen-containing products,19
and the CDC suggests that the benefits outweigh
the perceived risks (Category 2). The available lit-
erature is insufficient to determine if progestin-
only contraceptives increase the likelihood of ve-
nous thromboembolism among high-risk women.20
Complications of Cancer Treatment Affec-
ting the Selection of Contraception
Anemia
Hormonal contraceptive use in cancer patients
with anemia may be warranted. The incidence of
anemia in cancer patients is quite high, especially
in women with lung cancer (77% suffer from ane-
mia), and patients with gynecological cancer (81%
suffer from anemia). As women with cancer-in-
duced anemia have decreased functional capacity
and quality of life and shorter survival, efforts to
minimize menstrual blood loss with the use of pro-
gestin-containing contraceptive, particularly the
levonorgestrel IUS, may be warranted.21 The Cop-
per T380A may increase menstrual blood loss in
some women.22 The implant may cause an unpre-
dictable bleeding profile throughout the course of
its use.23
Osteoporosis
Osteoporosis is a common complication of chemo-
therapy. For patients with pre-existing bone den-
sity loss, the use of DMPA should be considered
with extreme caution even though the effect of
DMPA on bone mineral density have been found
to be reversible. One database study conducted in
the United Kingdom, concluded that the use of
DMPA is associated with a slight increase in the
risk of fracture. The use of contraceptive implants
affects the decrease in bone mineral density of the
radius and ulna, although no increased risk of frac-
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ture was confirmed. In contrast, the use of estro-
gen-containing contraceptives may have an advan-
tage in osteopenic women although there studies
are still contradictive.23
Immunosuppression
There are limited data on IUD use by women with
immunosuppression due to cancer treatment.
However, the WHO and the CDC state that IUD con-
traception is safe and can be used in women who
are immunosuppressed due to cancer treatment.24
Chest-Wall Radiation
Women who have received radiotherapy to the
chest-wall (Hodgkin’s lymphoma) have an increa-
sed risk of developing breast cancer. Therefore,
these patients should avoid the potential risk of ex-
ogenous estrogen or progestin.25 Nevertheless,
some clinicians still consider the use of combina-
tion hormonal contraceptives containing low-dose
estrogen or use of progestin-only contraceptives in
this case. This is based on the absence of studies
that conclude the effect of the use of contraceptives
containing estrogen and progestin leading to an in-
creased risk of breast cancer. T380A IUD contra-
ceptive use remains the primary choice in women
who received radiotherapy to the chest-wall, with
the levonorgestrel-containing IUS, which produce
the lowest serum hormone levels, as the second
choice.26,27
CONCLUSION
The information and education of contraception
should be provided for any woman considering
contraception. In women with cancer, it is recom-
mended that the use of contraception is reversible
and highly effective, such as IUD or implantable
contraceptive. Any type of contraception can be
used in women who have been free of cancer for
at least 6 months and had no history of hormone-
mediated cancers, not receiving chest-wall radia-
tion, no anemia, no osteoporosis and not experi-
encing venous thromboembolism.
The following recommendations are based on
good clinical evidence and consistent (Level A):
The Combined hormonal contraceptive methods
(containing estrogen and progestin) should be
avoided by women with active cancer or have been
treated for cancer in the last 6 months due to high
risk for venous thromboembolism. The use of
T380A IUD, highly effective, hormone-free method
is recommended for women with a history of
breast cancer. Moreover, Levonorgestrel-contain-
ing IUS may be used to minimize menstrual blood
loss.
The following recommendations are based on
limited or inconsistent scientific evidence (Level
B): Levonorgestrel-containing IUS has high efficacy
and decrease the risk of endometrial cancer with-
out breast cancer recurrence, and is recommended
in women who received tamoxifen. Among women
with a history of chest-wall radiation, use of total
systemic estrogen and progesterone contracepti-
ves should be avoided. Injectable progestin-only
contraception should be avoided in women with
osteopenia or osteoporosis. The use of estrogen-
containing contraception may be beneficial in wo-
men with osteopenia or osteoporosis. Intrauterine
contraceptive use is quite safe in women with imu-
nosuppression due to chemotherapy.
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